REPOTRECTINIB
repotrectinib 160 mg capsule, 60
REPOTRECTINIB (15288P)
15288P
Manner of administration:Oral
Restriction
Indication: Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer
(NSCLC)
Treatment phase: Initial treatment
Restriction
Indication: Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer
(NSCLC)
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 60 | # of repeats: 3 | DPMQ: $9,662.93 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Augtyro | |||||